ProQR Announces Management Change and Key Promotions
ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
Last proqr therapeutics n.v. - ordinary shares earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
proqr.com
Company Research
Source: GlobeNewswire
Key Updates Company announces departure of Noreen R. Henig, Chief Medical Officer, promotion of Peter Adamson to Senior Vice President Ophthalmology Franchise and Robert Friesen to Senior Vice President Science and Early Development.David M. Rodman, M.D., Chief Development Strategy Officer will assume leadership of clinical development at the Company. LEIDEN, the Netherlands, Oct. 26, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), (the “Company”), today announced that Noreen R. Henig, M.D., Chief Medical Officer, will leave ProQR effective November 4, 2017 to pursue a new opportunity, and will serve as a special advisor to the Company going forward. Chief Development Strategy Officer, David M. Rodman M.D, will assume leadership over clinical development. Additionally, the Company announced the promotion of Peter Adamson to Senior Vice President Ophthalmology Franchise and the promotion of Robert Friesen to Senior Vice President Science and Early Development. “In
Show less
Read more
Impact Snapshot
Event Time:
PRQR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRQR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRQR alerts
High impacting ProQR Therapeutics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRQR
News
- ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Chardan Capital from $2.00 to $2.50. They now have a "buy" rating on the stock.MarketBeat
- ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- ProQR Announces Year End 2023 Operating and Financial ResultsGlobeNewswire
- ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
PRQR
Earnings
- 11/7/23 - Miss
PRQR
Sec Filings
- 3/13/24 - Form 20-F
- 3/13/24 - Form 6-K
- 2/15/24 - Form 6-K
- PRQR's page on the SEC website